Johnson & Johnson Impact Ventures and Village Capital launched their first accelerator focused on culturally competent care this summer. Two startups were each awarded $100,000: Omaiven Health and Lucia Health Guidelines.
According to a preprint paper posted Tuesday, scientists at the company tested the drug, Prezista, against the virus in a cell culture, but found it had no activity. A combo therapy that includes Prezista's active ingredient is in clinical trials in China.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
While higher than the amounts that Purdue and Teva had to pay, an analyst wrote that the judgment is lower than what the state attorney general had sought. J&J said it plans to appeal the decision.
Redwood City, California-based Auris Health may also receive up to $2.35 billion in additional payments dependent on hitting certain predetermined milestones.
In a post on its website by an executive, the company said it would begin including list price and out-of-pocket cost information for an anticoagulant later this quarter.
The company currently has a product candidate in the late-discovery phase, an EGFR-targeting drug for lung cancer that would go after a resistance mechanism against existing kinase inhibitors.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
On day one of the Digital Health Summit at CES, leaders from three notable companies zeroed in on empowering patients. The panel discussion took place on the same day as an isolated power outage at CES, which truly inconvenienced attendees rather than empowered them.
Coming soon to a screen near you: more psoriasis ads. FDA has approved J&J's guselkumab (Tremfya) for use in moderate to severe plaque psoriasis. Despite plenty of competition, annual sales are expected to be north of $1 billion by 2022.
In an interview at ASCO 2017, head of the Prostate Cancer Foundation Jonathan Simons was heralding one of the biggest strides the field has seen in treating the most advanced form of the disease.
Japan's PeptiDream has once again turned small molecules into big business, signing a drug discovery agreement with Johnson & Johnson that could be worth up to $1.15 billion.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Two significant HIV announcements have already dropped at the Conference on Retroviruses and Opportunistic Infections in Seattle this week, courtesy of Gilead, GSK's ViiV Healthcare and J&J's Janssen Sciences Ireland.
Two U.S., startups and one translational lab from Australia have each been awarded $500,000 grants from J&J and Janssen, as part of the pharma giant's QuickFire Challenge.
Not quite a cure for the common cold, but close - PrEP Biopharm, a J&J licensee, is raising $25M for a nasal spray that it says can stop a cold in its tracks, preventing symptoms from materializing.
Insurers, U.S. regulators and now the FBI are probing the morcellator. The FBI is examining whether J&J pulled the hazardous device at the right time - since reports of its negative effects have been rolling in for many years.